Skip to main content
SpringerLink
Log in

Risikofaktoren bei Bienen- und Wespengiftallergie: aktuelle Bewertung

  • Übersicht
  • Published:
Allergo Journal Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Sturm GJ, Varga EM, Roberts G, Mosbech H, Bilò MB, Akdis CA et al. EAACI guidelines on allergen immunotherapy: hymenoptera venom allergy. Allergy 2018;73:744-64

  2. Chapsa M, Roensch H, Langner M, Beissert S, Bauer A. Predictors of severe anaphylaxis in hymenoptera venom allergy: the importance of absence of urticaria and angioedema. Ann Allergy Asthma Immunol 2020;125:72-7

  3. Fehr D, Micaletto S, Moehr T, Schmid-Grendelmeier P. Risk factors for severe systemic sting reactions in wasp (Vespula spp.) and honeybee (Apis mellifera) venom llergicpatients. Clin Transl Allergy. 2019;9:54

  4. Arzt L, Bokanovic D, Schwarz I, Schrautzer C, Massone C, Horn M et al. Hymenoptera stings in the head region induce impressive, but not severe sting reactions. Allergy 2016;71:1632-4

  5. Stoevesandt J, Hain J, Kerstan A, Trautmann A. Over-andunderestimated parameters in severe hymenoptera venominduced anaphylaxis: cardiovascular medication and absence of urticaria/angioedema. J Allergy Clin Immunol 2012;130:698-704

  6. Blum S, Gunzinger A, Müller UR, Helbling A. Influence of total and specific IgE, serum tryptase, and age on severity of allergic reactions to hymenoptera stings. Allergy 2010;66:222-8

  7. Guenova E, Volz T, Eichner M, Hoetzenecker W, Caroli U, Griesinger G et al. Basal serum tryptase as risk assessment for severe hymenoptera sting reactions in elderly. Allergy 2010;65:919-23

  8. Ruëff F, Przybilla B, Bilò MB, Müller U, Scheipl F, Aberer W et al. Predictors of severe systemic anaphylactic reactions in patients with hymenoptera venom allergy: importance of baseline serum tryptase - a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009;124:1047-54

  9. Muraro A, Fernández-Rivas M, Beyer K, Cardona V, Clark A, Eller E et al. The urgent need for a harmonized severity scoring system for acute allergic reactions. Allergy 2018;73:1792-800

  10. Turner PJ, Jerschow E, Umasunthar T, Lin R, Campbell DE, Boyle RJ. Fatal anaphylaxis: mortality rate and risk factors. J Allergy Clin Immunol Pract. 2017;5:1169-78

  11. Xu YS, Kastner M, Harada L, Xu A, Salter J, Waserman S. Anaphylaxis-related deaths in Ontario: a retrospective review of cases from 1986 to 2011. Allergy Asthma Clin Immunol 2014;10:38

  12. Golden DB, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM. Outcomes of allergy to insect stings in children, with and without venomimmunotherapy. N Engl J Med 2004;351:668-74

  13. Francuzik W, Ruëff F, Bauer A, Bilò MB, Cardona V, Christoff G et al. Phenotype and risk factors of venominduced anaphylaxis: a case-control study of the European Anaphylaxis Registry. J Allergy Clin Immunol 2021;147:653-662.e9

  14. Golden DB, Demain J, Freeman T, Graft D, Tankersley M, Tracy J et al. Stinging insect hypersensitivity: a practice parameter update 2016. Ann Allergy Asthma Immunol 2017;118:28-54

  15. Krishna MT, Ewan PW, Diwakar L, Durham SR, Frew AJ, Leech SC et al. Diagnosis and management of hymenoptera venom allergy: British Society for Allergy and Clinical Immunology (BSACI) guidelines. Clin Exp Allergy 2011;41:1201-20.

  16. Zanotti R, Lombardo C, Passalacqua G, Caimmi C, Bonifacio M, De Matteis G et al. Clonal mast cell disorders in patients with severe hymenoptera venom allergy and normal serum tryptase levels. J Allergy Clin Immunol 2015;136:135-9

  17. Álvarez-Twose I, González de Olano D, Sánchez-Muñoz L, Matito A, Jara-Acevedo M, Teodósio C et al. Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms. Int Arch Allergy Immunol 2012;157:275-80

  18. Sturm GJ, Herzog SA, Aberer W, Alfaya Arias T, Antolín-Amérigo D, Bonadonna P et al. Beta-blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venomimmunotherapy. Allergy 2021;76:2166-76

  19. Jerschow E, Lin RY, Scaperotti MM, McGinn AP. Fatal anaphylaxis in the United States, 1999-2010: temporalpatterns and demographic associations. J Allergy Clin Immunol 2014;134:1318-28

  20. Mullins RJ, Wainstein BK, Barnes EH, Liew WK, Campbell DE. Increases in anaphylaxis fatalities in Australia from 1997 to 2013. Clin Exp Allergy 2016;46:1099-110

  21. Bilò MB, Cichocka-Jarosz E, Pumphrey R, Oude-Elberink JN, Lange J, Jakob T et al. Self-medication of anaphylactic reactions due to hymenoptera stings - an EAACI task force consensus statement. Allergy 2016;71:931-43

  22. Christensen MJ, Eller E, Mortz CG, Brockow K, Bindslev-Jensen C. Wheat-dependent cofactor-augmented anaphylaxis: a prospective study of exercise, aspirin, and alcohol efficacy as cofactors. J Allergy Clin Immunol Pract 2019;7:114-21

  23. Wölbing F, Fischer J, Köberle M, Kaesler S, Biedermann T. About the role and underlying mechanisms of cofactors in anaphylaxis. Allergy 2013;68:1085-92

  24. Worm M, Francuzik W, Renaudin JM, Bilò MB, Cardona V, Scherer Hofmeier K et al. Factors increasing the risk for a severe reaction in anaphylaxis: ananalysis of data from the European Anaphylaxis Registry. Allergy 2018;73: 1322-30

  25. Vos B, van Anrooij B, van Doormaal JJ, Dubois AEJ, Oude Elberink JNG. Fatal anaphylaxis to yellow jacket stings in mastocytosis: options for identification and treatment of at risk patients. J Allergy Clin Immunol Pract 2017;5: 1264-71

  26. Gülen T, Hägglund H, Dahlén B, Nilsson G. High prevalence of anaphylaxis in patients with systemic mastocytosis - a single-centre experience. Clin Exp Allergy 2014;44:121-9

  27. Niedoszytko M, de Monchy J, van Doormaal JJ, Jassem E, Oude Elberink JN. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 2009;64:1237-45

  28. Álvarez-Twose I, Zanotti R, González de Olano D, Bonadonna P, Vega A, Matito A et al. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. J Allergy Clin Immunol 2014;133:520-8

  29. Lyons JJ, Chovanec J, O'Connell MP, Liu Y, Selb J, Zanotti R et al. Heritable risk for severe anaphylaxis associated with increased alpha-tryptase-encoding germline copy number at TPSAB1. J Allergy Clin Immunol 2021;147:622-32

  30. Le QT, Lyons JJ, Naranjo AN, Olivera A, Lazarus RA, Metcalfe DD et al. Impact of naturally forming human alpha/beta-tryptase heterotetramers in the pathogenesis of hereditary alpha-tryptasemia. J Exp Med 2019;216:2348-61

  31. Zink A, Schuster B, Winkler J, Eyerich K, Darsow U, Brockow K et al. Allergy and sensitization to hymenoptera venoms in unreferred adults with a high risk of sting exposure. World Allergy Organ J 2019; 12:100039

  32. Golden DB. Insect allergy in children. Curr Opin Allergy Clin Immunol 2006;6:289-93

  33. Stoevesandt J, Hosp C, Kerstan A, Trautmann A. Safety of 100 µg venom immunotherapy rush protocols in children compared to adults. Allergy Asthma Clin Immunol 2017;13:32

  34. Tejedor-Alonso MA, Farias-Aquino E, Perez-Fernandez E, Grifol-Clar E, Moro-Moro M, Rosado-Ingelmo A. Relationship between anaphylaxis and use of beta-blockers and angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis of observational studies. J Allergy Clin Immunol Pract 2019;7:879-97.e5

  35. Motosue MS, Bellolio MF, Van Houten HK, Shah ND, Campbell RL. Risk factors for severe anaphylaxis in the United States. Ann Allergy Asthma Immunol 2017; 119:356-61

  36. Müller UR. Cardiovascular disease and anaphylaxis. Curr Opin Allergy Clin Immunol 2007;7:337-41

  37. Marone G, Genovese A, Varricchi G, Granata F. Humanheart as a shockorganin anaphylaxis. Allergo J Int 2014; 23:60-6

  38. Cross B, Choudhury TR, Hindle M, Galasko G. Wasp sting induced STEMI with complete coronary artery occlusion: a case of Kounis syndrome. BMJ Case Rep 2017; https://doi. org/10.1136/bcr-2017-221256

  39. Aminiahidashti H, Laali A, Samakoosh AK, Gorji AM. Myocardial infarction following a bee sting: a case report of Kounis syndrome. Ann Card Anaesth 2016;19:375-8

  40. Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000; 30:1144-50

  41. Ingall M, Goldman G, Page LB. Beta-blockade in stinging insect anaphylaxis. JAMA 1984;251:1432

  42. Nassiri M,Babina M,Dölle S,Edenharter G,Ruëff F,Worm M. Ramipril and metoprolol intake aggravate human and murine anaphylaxis: evidence for direct mast cell priming. J Allergy Clin Immunol 2015;135:491-9

  43. Stoevesandt J, Hain J, Stolze I, Kerstan A, Trautmann A. Angiotensin-converting enzyme inhibitors do not impair the safety of hymenoptera venom immunotherapy buildupphase. Clin Exp Allergy 2014;44:747-55

  44. Boyle RJ, Elremeli M, Hockenhull J, Cherry MG, Bulsara MK, Daniels M et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev 2012;10:CD8838

  45. Stoevesandt J, Hosp C, Kerstan A, Trautmann A. Hymenoptera venom immunotherapy while maintaining cardiovascular medication: safe and effective. Ann Allergy Asthma Immunol 2015;114:411-6

  46. Brehler R, Wolf H, Kütting B, Schnitker J, Luger T. Safety of a two-day ultra rush insectvenom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections. J Allergy Clin Immunol 2000;105:1231-5

  47. Ruëff F, Przybilla B, Bilò MB, Müller U, Scheipl F, Aberer W, et al. Predictors of side effects during the buildup phase of venomimmunotherapy for hymenoptera venom allergy: the importance of baseline serum tryptase. J Allergy Clin Immunol. 2010;126:105-11

  48. Bilò MB, Severino M, Cilia M, Pio A, Casino G, Ferrarini E, et al. The VISYT trial: venom immunotherapy safety and tolerability with purified vs nonpurified extracts. Ann AllergyAsthma Immunol. 2009;103:57-61

  49. Mosbech H, Müller U. Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European Academy of Allergology and Clinical Immunology. Allergy. 2000;55:1005-10.

  50. Stoevesandt J, Hosp C, Kerstan A, Trautmann A. Risk stratification of systemic allergic reactions during hymenoptera venom immunotherapy buildup phase. J Dtsch Dermatol Ges 2014;12:244-55

  51. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: the World Allergy Organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol 2010; 125:569-574.e7

  52. Reimers A, Hari Y, Müller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebocontrolled trial. Allergy 2000;55:484-8

  53. Stretz E, Oppel EM, Rawer HC, Chatelain R, Mastnik S, Przybilla B et al. Overcoming severe adverse reactions to venom immunotherapy using anti-IgE antibodies in combination with a high maintenance dose. Clin Exp Allergy 2017;47:1631-9

  54. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987;79:660-77

  55. Müller UR, Haeberli G. Use of beta-blockers during immunotherapy for hymenoptera venom allergy. J AllergyClin Immunol 2005;115:606-10

  56. Blank S, Etzold S, Darsow U, Schiener M, Eberlein B, Russkamp D et al. Component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy. Hum Vaccin Immunother 2017;13:2482-9

  57. Ruiz B, Serrano P, Verdu M, Moreno C. Sensitization to Api m 1, Api m 2, and Api m 4: association with safety of bee venom immunotherapy. Ann Allergy Asthma Immunol 2015;114:350-2

  58. Bilò MB, Antonicelli L, Bonifazi F. Purified vs. nonpurified venom immunotherapy. Curr Opin Allergy Clin Immunol. 2010;10:330-6

  59. Frick M, Fischer J, Helbling A, Ruëff F, Wieczorek D, Ollert M et al. Predominant Api m 10 sensitization as risk factor for treatment failure in honey bee venom immunotherapy. J Allergy Clin Immunol 2016;138:1663-71.e9

  60. Jakob T, Rauber MM, Perez-Riverol A, Spillner E, Blank S. The honeybee venom major allergen Api m 10 (Icarapin) and its role in diagnostics and treatment of hymenoptera venom allergy. Curr Allergy Asthma Rep 2020;20:48

  61. Čerpes U, Arzt-Gradwohl L, Schrautzer C, Koch L, Bokanovic D, Laipold K et al. Simultaneous up-dosing of bee and vespid venom immunotherapy is safe. Allergy 2020;75:721-3

  62. Pospischil IM, Kagerer M, Cozzio A, Angelova-Fischer I, Guenova E, Ballmer-Weber B et al. Comparison of the safety profiles of 3 different hymenoptera venom immunotherapy protocols: a retrospective 2-center study of 143 patients. Int Arch Allergy Immunol 2020; 181:783-9

  63. González de Olano D, Álvarez-Twose I, Esteban-López MI, Sánchez-Muñoz L, de Durana MD, Vega A et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2008;121:519-26

  64. Jarkvist J, Salehi C, Akin C, Gülen T. Venom immunotherapy in patients with clonal mast cell disorders: IgG4 correlates withprotection. Allergy 2020;75:169-77

  65. Bonadonna P, González de Olano D, Zanotti R, Riccio A, De Ferrari L, Lombardo C et al. Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations. J Allergy Clin Immunol Pract 2013;1:474-8

  66. Ober AI, MacLean JA, Hannaway PJ. Life-threatening anaphylaxis to venom immunotherapy in a patient taking an angiotensin-converting enzyme inhibitor. J Allergy Clin Immunol 2003;112:1008-9

  67. Ruëff F, Vos B, Oude Elberink J, Bender A, Chatelain R, Dugas-Breit S et al. Predictors of clinical effectiveness of hymenoptera venom immunotherapy. Clin Exp Allergy 2014;44:736-46

  68. Bonadonna P, Zanotti R, Pagani M, Bonifacio M, Scaffidi L, Olivieri E et al. Anaphylactic reactions after discontinuation of hymenoptera venom immunotherapy: a clonal mast cell disorder should be suspected. J Allergy Clin Immunol Pract 2018;6:1368-72

  69. Oude Elberink JN, deMonchy JG, Kors JW, van Doormaal JJ, Dubois AE. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 1997;99:153-4

  70. Ruëff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001; 108:1027-32

  71. Ruëff F, Przybilla B, Müller U, Mosbech H. The sting challenge test in hymenoptera venom allergy. Position paper of the Subcommittee on Insect Venom Allergy of the European Academy of Allergology and Clinical Immunology. Allergy 1996;51:216-25

  72. Aßmus K, Meissner M, Kaufmann R, Valesky EM. Benefits and limitations of sting challenge in hymenoptera venom allergy. Allergol Select 2021;5:45-50

  73. Ruëff F, Przybilla B, Bilò MB, Müller U, Scheipl F, Seitz MJ et al. Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European Academy of Allergology and Clinical Immunology interest group on insect venom hypersensitivity. PLoSOne 2013;8:e63233

  74. Lerch E, Müller UR. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol 1998;101:606-12

  75. Ruiz-León B, Navas A, Serrano P, Espinazo M,Labrador-Horrillo M, Monsalve RI et al. Successful adaptation of bee venom immunotherapy in a patient monosensitized to Api m 10. J Investig Allergol Clin Immunol 2020; 30:296-8

  76. Golden DB, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Dose dependence of hymenoptera venom immunotherapy. J Allergy Clin Immunol 1981;67:370-4

  77. Goldberg A, Confino-Cohen R. Bee venom immunotherapy - How early is it effective? Allergy 2010;65:391-5

  78. Reisman RE. Duration of venom immunotherapy: relationship to the severity of symptoms of initial insect sting anaphylaxis. J Allergy Clin Immunol 1993;92:831-6

  79. Golden DB, Kwiterovich KA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol 1996;97:579-87

  80. Hafner T, DuBuske L, Kosnik M. Long-term efficacy of venom immunotherapy. Ann Allergy Asthma Immunol 2008;100:162-5

Download references

Finanzierung

Open-Access-Finanzierung der englischsprachigen Fassung dieser Übersichtsarbeit wurde ermöglicht und organisiert durch das Projekt DEAL.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg, Würzburg, Germany

    Johanna Stoevesandt

  2. Allergiezentrum Mainfranken, Klinik u. Poliklinik f. Dermatologie Univ. Würzburg, Josef-Schneider-Str. 2, 97080, Würzburg, Germany

    Axel Trautmann

Authors
  1. Johanna Stoevesandt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Axel Trautmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johanna Stoevesandt.

Ethics declarations

A. Trautmann gibt an, Beratungshonorare von ALK-Abelló, die nicht im Zusammenhang mit der eingereichten Arbeit stehen, erhalten zu haben.

J. Stoevesandt gibt an, dass keine Interessenkonflikte vorliegen.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags durch zwei unabhängige Gutachten geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stoevesandt, J., Trautmann, A. Risikofaktoren bei Bienen- und Wespengiftallergie: aktuelle Bewertung. Allergo J 31, 18–31 (2022). https://doi.org/10.1007/s15007-021-4938-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15007-021-4938-y

Schlüsselwörter

Search

Navigation